Paula T. Hammond
Dean of Engineering; Institute Professor; Koch Institute of Integrative Cancer Research
- Department
- Chemical Engineering
- Title
- Institute Professor
- Lab
- The Hammond Lab
Professor Paula T. Hammond is Institute Professor at the Massachusetts Institute of Technology and a member of MIT’s Koch Institute for Integrative Cancer Research. She is the Dean of the School of Engineering at MIT. Previously, she served as the Executive Vice Provost and as Vice Provost for Faculty from 2024 to January 2026, and as the Department Head of Chemical Engineering from 2015 to 2023.
She investigates electrostatic polymer systems for the delivery of drugs to specific parts of the body, including thin film coatings to release proteins that regenerate bone, dressings that release RNA to assist in wound healing, and her current primary area of work on nanoparticles that can bind to tumors specifically to treat cancer. She has had a particular focus on the development of new therapies for ovarian cancer that arm the immune system to help address both primary and recurrent tumors.
She received her S.B. at MIT, her M.S. at Georgia Institute of Technology, and her Ph.D. at MIT, with all her degrees in Chemical Engineering, followed by a postdoctoral fellowship in Chemistry at Harvard University.
Professor Paula Hammond was elected to the National Academy of Science in 2019, the National Academy of Engineering in 2017, the National Academy of Medicine in 2016, and the 2013 Class of the American Academy of Arts and Sciences. In January 2025, she was awarded the National Medal of Technology and Innovation. She is also a member of the National Academy of Inventors.
She received the Margaret H. Rousseau Pioneer Award for Lifetime Achievement by a Woman Chemical Engineer, the Benjamin Franklin Medal in Chemistry from the Franklin Institute and the 2025 Othmer Gold Medal. She is a former member of the Scientific Advisory Board of Moderna Therapeutics and currently serves as a Director on the Board of Alector Therapeutics, a public company, and Sail Biomedicines, a Flagship company.
Professor Hammond serves as a member of the Board at the MIT Engine. From 2021 to 2025, Professor Hammond also served on the President’s Council of Advisors on Science and Technology (PCAST).
